Claims

1. A compound having the formula



(I)

a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof; wherein

G is a direct bond or C_{1-10}alkanediyl optionally substituted with one or more substituents individually selected from the group of substituents consisting of hydroxy, C_{1-6}alkyloxy, Ar^1C_{1-6}alkyloxy, C_{1-6}alkylthio, Ar^1C_{1-6}alkylthio, $HO(-CH_2-CH_2-O)_n-$, C_{1-6}alkyloxy$(-CH_2-CH_2-O)_n-$ or Ar^1C_{1-6}alkyloxy$(-CH_2-CH_2-O)_n-$;

R^1 is Ar^1 or a monocyclic or bicyclic heterocycle being selected from piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydrofuranyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1*H*-imidazo[4,5-b]pyridinyl, 3*H*-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]-pyridinyl, 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl or a radical of formula



(c-1)



(c-2)



(c-3)



(c-4)



(c-5)



(c-6)



(c-7)



(c-8)

;

wherein each of said monocyclic or bicyclic heterocycles may optionally be substituted with 1 or where possible more, such as 2, 3, 4 or 5, substituents individually selected from the group of substituents consisting of halo, hydroxy, amino, cyano, carboxyl, C_{1-6}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, C_{1-6}alkyloxyC_{1-6}alkyl, Ar^1, Ar^1C_{1-6}alkyl, Ar^1C_{1-6}alkyloxy, hydroxyC_{1-6}alkyl, mono-or di(C_{1-6}alkyl)amino, mono-or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, polyhaloC_{1-6}alkyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkyl-SO_2-NR^{5c}-, Ar^1-SO_2-NR^{5c}-, C_{1-6}alkyloxycarbonyl, -C(=O)-$NR^{5c}R^{5d}$, HO(-CH_2-CH_2-O)$_n$-, halo(-CH_2-CH_2-O)$_n$-, C_{1-6}alkyloxy(-CH_2-CH_2-O)$_n$-, Ar^1C_{1-6}alkyloxy(-CH_2-CH_2-O)$_n$- and mono-or di(C_{1-6}alkyl)amino(-CH_2-CH_2-O)$_n$-;

each n independently is 1, 2, 3 or 4;

each m independently is 1 or 2;

each p independently is 1 or 2;

each t independently is 0, 1 or 2;

Q is R^7, pyrrolidinyl substituted with R^7, piperidinyl substituted with R^7 or homo-piperidinyl substituted with R^7 wherein

R^7 is C_{1-6}alkyl substituted with a heterocycle or R^7 is C_{1-6}alkyl substituted with both a radical –OR^8 and a heterocycle, wherein said heterocycle is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, hydroxy, carboxyl, C_{1-4}alkyloxycarbonyl, aminocarbonyl, mono- or di(C_{1-4}alkyl)aminocarbonyl, C_{1-4}alkylcarbonylamino, aminosulfonyl and mono- or di(C_{1-4}alkyl)aminosulfonyl;

R^8 is hydrogen, C_{1-6}alkyl or Ar^1C_{1-6}alkyl;

one of R^{2a} and R^{3a} is selected from halo, optionally mono- or polysubstituted C_{1-6}alkyl, optionally mono- or polysubstituted C_{2-6}alkenyl, nitro, hydroxy, Ar^2, $N(R^{4a}R^{4b})$, $N(R^{4a}R^{4b})$sulfonyl, $N(R^{4a}R^{4b})$carbonyl, C_{1-6}alkyloxy, Ar^2oxy, Ar^2C_{1-6}alkyloxy, carboxyl, C_{1-6}alkyloxycarbonyl, or -C(=Z)Ar^2; and the other one of R^{2a} and R^{3a} is hydrogen;

wherein

- =Z is =O, =CH-C(=O)-$NR^{5a}R^{5b}$, =CH_2, =CH-C_{1-6}alkyl, =N-OH or =N-O-C_{1-6}alkyl; and
- the optional substituents on C_{1-6}alkyl and C_{2-6}alkenyl can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydroxy, cyano, halo, nitro, $N(R^{4a}R^{4b})$, $N(R^{4a}R^{4b})$sulfonyl, Het, Ar^2, C_{1-6}alkyloxy, C_{1-6}alkyl-S(=O)$_t$, Ar^2oxy,

Ar^2-S(=O)$_t$, Ar^2C_{1-6}alkyloxy, Ar^2C_{1-6}alkyl-S(=O)$_t$, Het-oxy, Het-S(=O)$_t$, HetC_{1-6}alkyloxy, HetC_{1-6}alkyl-S(=O)$_t$, carboxyl, C_{1-6}alkyloxycarbonyl and -C(=Z)Ar^2;

in case R^{2a} is different from hydrogen then R^{2b} is hydrogen, C_{1-6}alkyl or halogen and R^{3b} is hydrogen;

in case R^{3a} is different from hydrogen then R^{3b} is hydrogen, C_{1-6}alkyl or halogen and R^{2b} is hydrogen;

R^{4a} and R^{4b} can be the same or can be different relative to one another, and are each independently selected from the group of substituents consisting of hydrogen, C_{1-6}alkyl, Ar^2C_{1-6}alkyl, (Ar^2)(hydroxy)C_{1-6}alkyl, Het-C_{1-6}alkyl, hydroxyC_{1-6}alkyl, mono- and di-(C_{1-6}alkyloxy)C_{1-6}alkyl, (hydroxyC_{1-6}alkyl)oxyC_{1-6}alkyl, Ar^1C_{1-6}alkyloxy-C_{1-6}alkyl, dihydroxyC_{1-6}alkyl, (C_{1-6}alkyloxy)(hydroxy)C_{1-6}alkyl, (Ar^1C_{1-6}alkyloxy)(hydroxy)C_{1-6}alkyl, Ar^1oxy-C_{1-6}alkyl, (Ar^1oxy)(hydroxy)-C_{1-6}alkyl, aminoC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)amino-C_{1-6}alkyl, carboxylC_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminocarbonylC_{1-6}alkyl, C_{1-6}alkylcarbonylC_{1-6}alkyl, (C_{1-4}alkyl-oxy)$_2$P(=O)-C_{1-6}alkyl, (C_{1-4}alkyloxy)$_2$P(=O)-O-C_{1-6}alkyl, aminosulfonyl-C_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminosulfonyl-C_{1-6}alkyl, C_{1-6}alkylcarbonyl, Ar^2carbonyl, Het-carbonyl, Ar^2C_{1-6}alkylcarbonyl, Het-C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, aminosulfonyl, mono- and di(C_{1-6}alkyl)aminosulfonyl, Ar^2sulfonyl, Ar^2C_{1-6}alkylsulfonyl, Ar^2, Het, Het-sulfonyl, HetC_{1-6}alkylsulfonyl;

R^5 is hydrogen or C_{1-6}alkyl;

R^{5a} and R^{5b} can be the same or can be different relative to one another, and are each independently hydrogen or C_{1-6}alkyl; or

R^{5a} and R^{5b} taken together may form a bivalent radical of formula -$(CH_2)_s$- wherein s is 4 or 5;

R^{5c} and R^{5d} can be the same or can be different relative to one another, and are each independently hydrogen or C_{1-6}alkyl; or

R^{5c} and R^{5d} taken together may form a bivalent radical of formula -$(CH_2)_s$- wherein s is 4 or 5;

Ar^1 is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, polyhaloC_{1-6}alkyl, and C_{1-6}alkyloxy;

Ar^2 is phenyl, phenyl annelated with C_{5-7}cycloalkyl, or phenyl substituted with 1 or more, such as 2, 3, 4 or 5, substituents selected from halo, cyano, C_{1-6}alkyl, Het-C_{1-6}alkyl, Ar^1-C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6}alkenyl, cyanoC_{2-6}alkenyl, R^{6b}-O-C_{3-6}alkenyl, C_{2-6}alkynyl, cyanoC_{2-6}alkynyl, R^{6b}-O-C_{3-6}alkynyl, Ar^1, Het, R^{6b}-O-, R^{6b}-S-, R^{6c}-SO-, R^{6c}-SO_2-, R^{6b}-O-C_{1-6}alkyl-SO_2-, -N($R^{6a}R^{6b}$), polyhalo-

C_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, polyhaloC_{1-6}alkylthio, R^{6c}-C(=O)-, R^{6b}-O-C(=O)-, N($R^{6a}R^{6b}$)-C(=O)-, R^{6b}-O-C_{1-10}alkyl, R^{6b}-S-C_{1-6}alkyl, R^{6c}-S(=O)$_2$-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-C_{1-6}alkyl, R^{6c}-C(=O)-C_{1-6}alkyl, R^{6b}-O-C(=O)-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-C(=O)-C_{1-6}alkyl, R^{6c}-C(=O)-NR^{6b}-, R^{6c}-C(=O)-O-, R^{6c}-C(=O)-NR^{6b}-C_{1-6}alkyl, R^{6c}-C(=O)-O-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-S(=O)$_2$-, H_2N-C(=NH)-;

R^{6a} is hydrogen, C_{1-6}alkyl, Ar^1, Ar^1C_{1-6}alkyl, C_{1-6}alkylcarbonyl, Ar^1carbonyl, Ar^1C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, Ar^1sulfonyl, Ar^1C_{1-6}alkylsulfonyl, C_{1-6}alkyloxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, hydroxyC_{1-6}alkyl, (carboxyl)-C_{1-6}alkyl, (C_{1-6}alkyloxycarbonyl)-C_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminocarbonylC_{1-6}alkyl, aminosulfonyl-C_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminosulfonyl-C_{1-6}alkyl, Het, Het-C_{1-6}alkyl, Het-carbonyl, Het-sulfonyl, Het-C_{1-6}alkylcarbonyl;

R^{6b} is hydrogen, C_{1-6}alkyl, Ar^1 or Ar^1C_{1-6}alkyl;

R^{6c} is C_{1-6}alkyl, Ar^1 or Ar^1C_{1-6}alkyl;

Het is a heterocycle being selected from tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidinonyl, furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, tetrahydroquinolinyl, quinolinyl, isoquinolinyl, benzodioxanyl, benzodioxolyl, indolinyl, indolyl, each of said heterocycle may optionally be substituted with oxo, amino, Ar^1, C_{1-4}alkyl, aminoC_{1-4}alkyl, Ar^1C_{1-4}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)amino, (hydroxyC_{1-6}alkyl)amino, and optionally further with one or two C_{1-4}alkyl radicals.

2. A compound according to claim 1 wherein the compound has the formula:



(I-c)

wherein R^5, G, R^1, R^{2a}, R^{2b}, R^{3a}, R^{3b} are as claimed in claim 1 and

Alk^1 is C_{1-6}alkanediyl;

R^{7a} is a heterocycle which is selected from the group consisting of oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydro-oxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine and

1,1-dioxohexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C_{1-6}alkyl, hydroxy, carboxyl, C_{1-4}alkyloxycarbonyl, aminocarbonyl, mono- or di(C_{1-4}alkyl)aminocarbonyl, C_{1-4}alkylcarbonylamino, aminosulfonyl and mono- or di(C_{1-4}alkyl)aminosulfonyl.

3. A compound according to claim 1 wherein the compound has the formula:



(I-d)

wherein R^5, G, R^1, R^{2a}, R^{2b}, R^{3a}, R^{3b} are as claimed in claim 1 and Alk^1 and R^{7a} are as claimed in claim 2.

4. A compound according to claim 1 wherein the compound has the formula:



(I-c-1)

or



(I-c-2)

wherein R^5, G, R^1, R^{2a}, R^{2b}, R^{3a}, R^{3b} are as claimed in claim 1, and Alk^1 and R^{7a} are as claimed in claim 2.

5. A compound according to claim 1 wherein the compound has the formula:



(I-c-3)

wherein R^5, G, R^1, R^{3b}, R^{4a} are as claimed in claim 1, and Alk^1 and R^{7a} are as claimed in claim 2; and

R^9, R^{10}, R^{11} each independently are selected from halo, cyano, C_{1-6}alkyl, Het-C_{1-6}alkyl, Ar^1-C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6}alkenyl, cyanoC_{2-6}alkenyl,

R^{6b}-O-C_{3-6}alkenyl, C_{2-6}alkynyl, cyanoC_{2-6}alkynyl, R^{6b}-O-C_{3-6}alkynyl, Ar^1, Het, R^{6b}-O-, R^{6b}-S-, R^{6c}-SO-, R^{6c}-SO_2-, R^{6b}-O-C_{1-6}alkyl-SO_2-, -N($R^{6a}R^{6b}$), polyhaloC_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, polyhaloC_{1-6}alkylthio, R^{6c}-C(=O)-, R^{6b}-O-C(=O)-, N($R^{6a}R^{6b}$)-C(=O)-, R^{6b}-O-C_{1-6}alkyl, R^{6b}-S-C_{1-6}alkyl, R^{6c}-S(=O)$_2$-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-C_{1-6}alkyl, R^{6c}-C(=O)-C_{1-6}alkyl, R^{6b}-O-C(=O)-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-C(=O)-C_{1-6}alkyl, R^{6c}-C(=O)-NR^{6b}-, R^{6c}-C(=O)-O-, R^{6c}-C(=O)-NR^{6b}-C_{1-6}alkyl, R^{6c}-C(=O)-O-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-S(=O)$_2$-, H_2N-C(=NH)-;

and Alk is C_{1-6}alkanediyl.

6. A compound according to claim 1 wherein the compound has the formula:



(I-c-4)

wherein R^5, G, R^1, R^{4a}, R^{2b} are as claimed in claim 1, and Alk^1 and R^{7a} are as claimed in claim 2; R^9, R^{10}, R^{11} and Alk are as claimed in claim 5.

7. A compound according to claim 1 wherein the compound has the formula:



(I-c-5)

wherein R^5, G, R^1, R^{3b} are as claimed in claim 1, and Alk^1 and R^{7a} are as claimed in claim 2; R^9, R^{10} and Alk are as claimed in claim 5; and

R^{6a} is hydrogen, C_{1-6}alkyl, Ar^1, Ar^1C_{1-6}alkyl, C_{1-6}alkylcarbonyl, Ar^1carbonyl, Ar^1C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, Ar^1sulfonyl, Ar^1C_{1-6}alkylsulfonyl, C_{1-6}alkyloxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, hydroxyC_{1-6}alkyl, (carboxyl)-C_{1-6}alkyl, (C_{1-6}alkyloxycarbonyl)-C_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminocarbonylC_{1-6}alkyl, aminosulfonyl-C_{1-6}alkyl, mono- and di(C_{1-6}alkyl)aminosulfonyl-C_{1-6}alkyl, Het, Het-C_{1-6}alkyl, Het-carbonyl, Het-sulfonyl, Het-C_{1-6}alkylcarbonyl;

R^{6b} is hydrogen, C_{1-6}alkyl, Ar^1 or Ar^1C_{1-6}alkyl.

8. A compound according to claim 1 wherein the compound has the formula:



(I-c-6)

wherein R^5, G, R^1, R^{2b} are as claimed in claim 1, and Alk^1 and R^{7a} are as claimed in claim 2; R^9, R^{10} and Alk are as claimed in claim 5; and R^{6a} and R^{6b} are as claimed in claim 7.

9. A compound according to claim 1 wherein the compound has the formula:



(I-d-1)

or of formula:



(I-d-2)

wherein R^5, G, R^1, R^{2a}, R^{2b}, R^{3a}, R^{3b} are as claimed in claim 1, and Alk^1 and R^{7a} are as claimed in claim 2.

10. A compound according to any of claims 2 to 10, wherein R^{7a} is a heterocycle selected from the group consisting of oxazolidine, thiazolidine, morpholinyl, thiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine; wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminocarbonylC_{1-6}alkyl.

11. A compound according to any of claims 2 to 10, wherein R^{7a} is a heterocycle, wherein said heterocycle is oxazolidine, thiazolidine, morpholinyl or thiomorpholinyl, wherein each of said heterocyle may be optionally substituted with one or two substituents selected from the group consisting of C_{1-6}alkyl, hydroxy-C_{1-6}alkyl, aminocarbonylC_{1-6}alkyl.

12. A compound according to any of claims 2 to 10, wherein R^{7a} is morpholinyl.

13. A compound according to any of claims 5 to 8, wherein Alk is methylene.

14. A compound according to any of claims 2 to 10, wherein Alk^1 is C_{1-4}alkanediyl.

15. A compound according to any of claims 5 to 8, wherein R^9, R^{10}, R^{11} are selected from halo, cyano, C_{1-6}alkyl, Het-C_{1-6}alkyl, Ar^1-C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6}alkenyl, cyanoC_{2-6}alkenyl, R^{6b}-O-C_{3-6}alkenyl, C_{2-6}alkynyl, cyanoC_{2-6}alkynyl, R^{6b}-O-C_{3-6}alkynyl, Ar^1, Het, R^{6b}-O-, R^{6b}-S-, R^{6c}-SO-, R^{6c}-SO_2-, R^{6b}-O-C_{1-6}alkyl-SO_2-, -N($R^{6a}R^{6b}$), CF_3, R^{6c}-C(=O)-, R^{6b}-O-C(=O)-, N($R^{6a}R^{6b}$)-C(=O)-, R^{6b}-O-C_{1-6}alkyl, R^{6b}-S-C_{1-6}alkyl, R^{6c}-S(=O)$_2$-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-C_{1-6}alkyl, R^{6c}-C(=O)-C_{1-6}alkyl, R^{6b}-O-C(=O)-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-C(=O)-C_{1-6}alkyl and R^{6c}-C(=O)-NR^{6b}-, H_2N-C(=NH)-.

16. A compound according to any of claims 5 to 8, wherein R^9, R^{10}, R^{11} are selected from C_{1-6}alkyl, Het-C_{1-6}alkyl, Ar^1-C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6}alkenyl, cyano-C_{2-6}alkenyl, R^{6b}-O-C_{3-6}alkenyl, C_{2-6}alkynyl, cyanoC_{2-6}alkynyl, R^{6b}-O-C_{3-6}alkynyl, R^{6b}-O-C_{1-6}alkyl, R^{6b}-S-C_{1-6}alkyl, R^{6c}-S(=O)$_2$-C_{1-6}alkyl, N($R^{6a}R^{6b}$)-C_{1-6}alkyl, R^{6b}-O-C(=O)-C_{1-6}alkyl and N($R^{6a}R^{6b}$)-C(=O)-C_{1-6}alkyl;

17. A compound according to any of claims 5 to 8, wherein R^9, R^{10}, R^{11} are selected from C_{1-6}alkyl, Het-C_{1-6}alkyl, Ar^1-C_{1-6}alkyl, cyanoC_{1-6}alkyl, C_{2-6}alkenyl, cyano-C_{2-6}alkenyl, C_{2-6}alkynyl, cyanoC_{2-6}alkynyl, R^{6b}-O-C_{1-6}alkyl, amino-S(=O)$_2$-C_{1-6}alkyl, R^{6b}-O-C(=O)-C_{1-6}alkyl, amino-C(=O)-C_{1-6}alkyl, mono- and diamino-C(=O)-C_{1-6}alkyl;

18. A compound according to any of claims 5 to 8, wherein R^9, R^{10}, R^{11} are C_{1-6}alkyl or R^{6b}-O-C_{1-6}alkyl; and $R^{10}$and/or R^{11} may also be hydrogen.

19. A compound according to any of claims 1 to 18, wherein G is C_{1-10}alkanediyl.

20. A compound according to any of claims 1 to 18, wherein G is methylene.

21. A compound according to any of claims 1 to 19 wherein R^1 is Ar^1, quinolinyl, benzimidazolyl, a radical of formula



(c-4)

pyrazinyl, or pyridyl; or wherein Ar^1, quinolinyl, benzimidazolyl, a radical of formula (c-4) may be substituted with 1 or where possible with 2 or 3 substituents independently selected from the group consisting of halo, hydroxy, amino, cyano, carboxyl, C_{1-6}alkyl, C_{1-6}alkyloxy, C_{1-6}alkylthio, C_{1-6}alkyloxyC_{1-6}alkyl, Ar^1, Ar^1C_{1-6}alkyl, Ar^1C_{1-6}alkyloxy, hydroxyC_{1-6}alkyl, mono-or di(C_{1-6}alkyl)amino, mono-or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, polyhaloC_{1-6}alkyl, C_{1-6}alkylcarbonylamino, C_{1-6}alkyl-SO_2-NR^{5c}-, Ar^1-SO_2-NR^{5c}-, C_{1-6}alkyloxycarbonyl, -C(=O)-$NR^{5c}R^{5d}$, HO(-CH_2-CH_2-O)$_n$-, halo(-CH_2-CH_2-O)$_n$-, C_{1-6}alkyloxy(-CH_2-CH_2-O)$_n$-, Ar^1C_{1-6}alkyloxy(-CH_2-CH_2-O)$_n$- and mono-or di(C_{1-6}alkyl)amino(-CH_2-CH_2-O)$_n$-; wherein each n independently is 1, 2, 3 or 4; each m independently is 1 or 2; Ar^1, R^{5c}, R^{5d} are as claimed in claim 1.

22. A compound according to any of claims 1 to 20 wherein R^1 is Ar^1, quinolinyl, benzimidazolyl or a radical of formula (c-4) wherein m is 2, pyrazinyl, or pyridyl, wherein each of these radicals may optionally be substituted with one, two or three radicals selected from the group consisting of halo, hydroxy, C_{1-6}alkyl, C_{1-6}alkyloxy, Ar^1C_{1-6}alkyloxy, (C_{1-6}alkyloxy)C_{1-6}alkyloxy.

23. A compound according to any of claims 1 to 20 wherein R^1 is phenyl optionally substituted with one, two or three radicals selected from the group consisting of halo, hydroxy, C_{1-6}alkyl, C_{1-6}alkyloxy; quinolinyl; a radical (c-4) wherein m is 2, optionally substituted with up to two radicals selected from C_{1-6}alkyl; benzimidazolyl optionally substituted with C_{1-6}alkyl; pyridyl optionally substituted with one or two radicals selected from hydroxy, halo, C_{1-6}alkyl, benzyloxy and C_{1-6}alkyloxy, pyrazinyl optionally substituted with up to three radicals selected from C_{1-6}alkyl; or pyridyl substituted or optionally substituted with one or two radicals selected from the group consisting of halo, hydroxy, C_{1-6}alkyl, C_{1-6}alkyloxy, Ar^1C_{1-6}alkyloxy, (C_{1-6}alkyloxy)C_{1-6}alkyloxy.

24. A compound according to any of claims 1 to 20 wherein R^1 is pyridyl optionally substituted with one or two radicals selected from hydroxy, halo, C_{1-6}alkyl, benzyloxy and C_{1-6}alkyloxy,

25. A compound according to any of claims 1 to 20 wherein R^1 is pyridyl optionally substituted with one or two radicals selected from hydroxy and C_{1-6}alkyl. C_{1-6}alkyloxy,

25. A compound according to any of claims 1 to 25, wherein, where applicable, one of R^{2a} and R^{3a} is selected from -N($R^{4a}R^{4b}$), ($R^{4a}R^{4b}$)N-CO-, C_{1-6}alkyl substituted with one or two substituents selected from hydroxy, cyano, Ar^2, Het or -N($R^{4a}R^{4b}$) and C_{2-6}alkenyl substituted with cyano or Ar^2; and the other one of R^{2a} and R^{3a} is hydrogen; and
in case R^{2a} is different from hydrogen then R^{2b} is hydrogen, C_{1-6}alkyl or halogen and R^{3b} is hydrogen;
in case R^{3a} is different from hydrogen then R^{3b} is hydrogen, C_{1-6}alkyl or halogen and R^{2b} is hydrogen.

26. A compound according to any of claims 1 to 25, wherein, where applicable, one of R^{2a} and R^{3a} is selected from ($R^{4a}R^{4b}$)N-CO-; C_{1-6}alkyl optionally substituted with hydroxy, Ar^2, Het or -N($R^{4a}R^{4b}$); and C_{2-6}alkenyl substituted with Ar^1; and the other one of R^{2a} and R^{3a} is hydrogen; or
in case R^{2a} is different from hydrogen then R^{2b} is hydrogen or C_{1-6}alkyl and R^{3b} is hydrogen;
in case R^{3a} is different from hydrogen then R^{3b} is hydrogen or C_{1-6}alkyl and R^{2b} is hydrogen;
Ar^2, Het, R^{4a} and R^{4b} are as in the definitions of the compounds of formula (I) or as in any subgroup specified herein.

27. A compound according to any of claims 25 or 26, wherein, where applicable, R^{2b} and R^{3b} are both hydrogen.

28. A compound according to claim 1, wherein the compound is 2-[6-{[2-(3-hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol.

29. A compound as claimed in any one of claims 1 to 28 for use as a medicine.

30. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as described in any one of claims 1 to 28.

31. The use of a compound as claimed in any of claims 1 to 28 for the manufacture of a medicament for inhibiting RSV.

32. A process for preparing a compound as claimed in any of claims 1 to 28, said process comprising

(a) reacting an intermediate of formula (II) with a reagent (III) as in the following reaction scheme:



(II) (III) (I)

(b) reducing a compound (I-1-a) or (I-1-b) to obtain a compound (I-2-a) or (I-2-b) and subsequently oxidizing the alcohol group in (I-2-a) or (I-2-b) with a mild oxidant to obtain an intermediate (I-3-a) or (I-3-b) and subsequently alkylating (I-3-a) or (I-3-b) to obtain (I-4-a) or (I-4-b), which is further alkylated to obtain (I-5-a) or (I-5-b) as in the following reaction schemes wherein R^{12} is C_{1-6}alkyl wherein is R^{4a} and R^{4b} are as claimed in claims 1 to 28 but are other than hydrogen.



(I-1-a) (I-2-a)



(c) converting the alcohol group in (I-2-a) or (I-2-b) to a leaving group and subsequently reacting the thus obtained products with an amine thus obtaining (I-6-a) or (I-6-b)





(d) converting an intermediate (I-3-a) or (I-3-b) to a compound (I-7-a) or (I-7-b) using a Wittig or Wittig-Horner procedure; selectively reducing the double bond in (I-7-a) or (I-7-b) thus obtaining compounds (I-8-a) or (I-8-b); reducing the cyano group in (I-9-a) or (I-9-b) to a methylene-amine group thus obtaining (I-10-a) or (I-10-b); mono- or dialkylating the latter thus obtaining compounds (I-11-a) or (I-11-b) ; or (I-12-a) or (I-12-b), wherein Alk^1 is C_{4-6}alkanediyl, R^{2a-1} is any of the substituents on alkenyl as defined in any of claims 1 – 28, and preferably R^{2a-1} is Ar^2 or CN:







(I-9-a) (I-10-a)



(I-11-a)



(I-12-a)



(I-3-b) (I-7-b)



(I-7-b) (I-8-b)



(I-9-b) (I-10-b)



(I-11-a)



(I-12-b)

and optionally converting the thus obtained compounds of formula (I) into their pharmaceutically acceptable base-addition or acid addition salt form by treatment with a suitable base or acid and conversely treating the base-addition or acid addition salt form with an acid or a base to obtain the free form of the compound of formula (I).